Overview

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of Stimulan-VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis of the Forefoot.

Status:
Not yet recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate the safety and between-group effect size of Stimulan-VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO) of the forefoot.

Phase:

Phase 2

Details

Lead Sponsor:

Biocomposites Ltd

Collaborator:

Parexel

Treatments:

Anti-Bacterial Agents